Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026--Phase 1a clinical ...

CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on ...

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

Gene editing reduced cholesterol by about 50% in an extremely small sample of patients over a year of follow-up, according to ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

The next six months may be decisive for the biotech.

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and ...

The CRISPR gene editing market is estimated at USD 4 billion in 2025 and is projected to reach USD 22 billion by 2035, expanding at a CAGR of 18.6% during the forecast period 2026–2035. The market is ...

This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.

It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...